Older age, male gender, advanced liver cirrhosis, fatty liver, and a high posttreatment serum alpha-fetoprotein (AFP) level are risk factors for HCC formation in IFN-treated individuals who achieve SVR 25, 26. The gene discussed is AFP; the disease is cirrhosis of liver.